Dana raises 2026 revenue outlook after strong sales performance

Insmed has increased its BRINSUPRI revenue guidance and expanded its peak sales outlook following strong Q2 growth. Similarly, Iovance Biotherapeutics reported record Q2 revenue and is reviewing its 2026 outlook due to high Amtagvi demand. Additionally, Dana has raised its 2026 revenue outlook following a period of strong sales performance. All three companies are leveraging positive quarterly results to adjust their long-term financial expectations upward based on current market demand and sales success.